Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Agenus Inc

Healthcare US AGEN

3.22USD
-0.16(4.73%)

Last update at 2026-06-03T20:00:00Z

Day Range

3.213.42
LowHigh

52 Week Range

2.637.34
LowHigh

Fundamentals

  • Previous Close 3.38
  • Market Cap150.14M
  • Volume466091
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.55700M
  • Revenue TTM114.20M
  • Revenue Per Share TTM3.84
  • Gross Profit TTM 110.22M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3.08300M -232.27100M -257.43700M -230.65600M -28.72400M
Minority interest 3.20M 5.06M 12.39M -10.58200M -4.79800M
Net income 0.12M -227.21200M -245.76100M -271.51500M -94.69600M
Selling general administrative 54.39M 71.88M 78.74M 81.01M 76.36M
Selling and marketing expenses - - 13.59M - -
Gross profit 103.17M -52.55100M -81.36600M -99.23500M 113.59M
Reconciled depreciation 10.00M 13.34M 10.28M 6.95M 6.79M
Ebit -20.55600M -114.64500M -159.51200M -179.42700M 42.28M
Ebitda -10.55700M -101.30200M -145.92400M -160.72500M 49.07M
Depreciation and amortization 10.00M 13.34M 13.59M 18.70M 6.79M
Non operating income net other - - - 12.57M 11.25M
Operating income -20.55600M -120.47500M -159.54900M -179.42700M 42.28M
Other operating expenses 134.75M 223.94M 315.86M 278.27M 258.44M
Interest expense 55.62M 117.63M 97.92M 61.86M 65.72M
Tax provision - - - - -
Interest income - - - - -
Net interest income -55.27300M -117.62600M -71.07000M -61.86300M -65.71900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -11.67600M 40.86M 65.97M
Total revenue 114.20M 103.46M 156.31M 98.02M 295.67M
Total operating expenses 123.73M 67.92M 78.18M 81.01M 76.36M
Cost of revenue 11.02M 156.01M 237.68M 197.26M 182.08M
Total other income expense net 17.47M -111.79600M -97.88800M -51.22900M -71.00300M
Discontinued operations - - - - -
Net income from continuing ops -3.08300M -232.27100M -282.95700M -228.71900M -28.72400M
Net income applicable to common shares - - - -220.28600M -24.13700M
Preferred stock and other adjustments - - - 0.21M 0.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 226.80M 226.27M 313.91M 413.56M 465.96M
Intangible assets 3.04M 3.38M 4.41M 6.23M 8.49M
Earning assets - - - - -
Other current assets 128.61M 4.73M 10.47M 3.19M 3.17M
Total liab 504.66M 532.70M 462.30M 468.46M 418.05M
Total stockholder equity -271.11100M -326.38000M -160.33100M -61.27800M 34.44M
Deferred long term liab - - - - -
Other current liab 83.11M 150.05M 48.74M 133.23M 110.68M
Common stock 0.35M 0.24M 3.94M 3.06M 2.57M
Capital stock 0.35M 0.24M 3.94M 3.06M 2.57M
Retained earnings -2182.76500M -2182.88000M -1955.66800M -1709.90700M -1489.83300M
Other liab - - - 191.33M 205.86M
Good will 24.09M 24.09M 24.72M 25.47M 24.88M
Other assets - - - 4.45M 9.54M
Cash 3.00M 40.44M 76.11M 178.67M 291.93M
Cash and equivalents - - - - -
Total current liabilities 323.49M 221.40M 255.90M 188.95M 156.94M
Current deferred revenue 1.14M 0.03M 0.02M 12.27M 12.43M
Net debt 331.90M 54.43M 274.14M -100.24600M -233.64400M
Short term debt 156.25M 9.85M 145.69M 2.52M 3.35M
Short long term debt 44.66M 2.70M 0.15M 0.57M 0.73M
Short long term debt total 334.90M 94.87M 350.25M 78.43M 58.29M
Other stockholder equity 1911.74M 1857.66M 1478.43M 1231.10M 1054.25M
Property plant equipment - - - 133.02M 91.08M
Total current assets 133.44M 45.57M 112.42M 213.12M 331.97M
Long term investments 24.28M 0.00000M - - -
Net tangible assets - - - 159.25M 1.08M
Short term investments - - 0.00000M 14.68M 14.99M
Net receivables 1.83M 0.41M 25.84M 2.74M 1.52M
Long term debt - 30.47M 12.77M 12.58M 12.82M
Inventory - - 0.00000M 13.83M 20.36M
Accounts payable 82.99M 61.47M 61.45M 40.94M 30.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 6.38M 13.47M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.43900M -1.39800M -0.95500M 0.92M 1.49M
Additional paid in capital - - - - -
Common stock total equity - - - 3.06M 2.57M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1709.90700M -1489.83300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.74200M 5.83M 5.67M 4.45M 9.54M
Deferred long term asset charges - - - - -
Non current assets total 93.36M 180.70M 201.50M 200.43M 133.98M
Capital lease obligations 11.24M 61.70M 65.10M 65.27M 44.74M
Long term debt total - - - 12.58M 12.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.84M 0.03M 3.40M 0.37M -14.99200M
Change to liabilities - - - 8.53M -11.00800M
Total cashflows from investing activities 0.03M 0.03M 3.40M -33.61000M -43.15000M
Net borrowings 2.35M 9.52M -8.92600M -0.49000M -1.31700M
Total cash from financing activities 122.84M 122.84M 119.87M 95.83M 225.26M
Change to operating activities - - - 27.84M 1.66M
Net income -232.27100M -232.27100M -257.43700M -230.65600M -28.72400M
Change in cash -35.70800M -35.70800M -101.56400M -113.25700M 192.09M
Begin period cash flow 79.78M 79.78M 181.34M 294.60M 102.50M
End period cash flow 44.07M 44.07M 79.78M 181.34M 294.60M
Total cash from operating activities -158.31500M -158.31500M -224.20200M -175.37300M 10.14M
Issuance of capital stock 36.14M 38.82M 133.16M 99.21M 220.65M
Depreciation 13.34M 13.34M 13.59M 6.95M 6.79M
Other cashflows from investing activities 0.02M 0.02M 3.36M 19.08M 5.66M
Dividends paid - - - - -9.13200M
Change to inventory - - - - -6.19100M
Change to account receivables -1.72800M 25.34M -23.46100M 0.12M -0.39400M
Sale purchase of stock -0.08700M 0.00000M -5.17200M -3.78900M -1.65400M
Other cashflows from financing activities 84.27M 74.50M 0.81M 0.90M 16.72M
Change to netincome - - - 70.39M 37.03M
Capital expenditures 0.58M 0.58M 9.95M 53.06M 33.81M
Change receivables - - - 0.12M -0.39400M
Cash flows other operating - - - -30.70500M -63.46600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -113.15300M 192.26M
Change in working capital 27.33M 32.60M 10.76M 24.08M -9.74300M
Stock based compensation 17.39M 17.39M 22.87M 18.34M 19.58M
Other non cash items 15.89M 10.62M -13.97800M 5.92M 31.75M
Free cash flow -158.89100M -158.89100M -234.15600M -228.43500M -23.66900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGEN
Agenus Inc		 -0.16 4.73% 3.22 - 1.78 1.31 218.62 1.78 3.27
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus Inc

3 Forbes Road, Lexington, MA, United States, 02421-7305

Key Executives

Name Title Year Born
Dr. Garo H. Armen Ph.D. Founder, Exec. Chairman & CEO 1953
Ms. Christine M. Klaskin VP of Fin., Principal Financial Officer & Principal Accounting Officer 1966
Dr. Steven J. O'Day M.D., Ph.D. Chief Medical Officer 1962
Dr. Jennifer S. Buell Ph.D. Pres & CEO of MiNK Therapeutics 1975
Craig Winter Chief Information Officer NA
Regina Grebla Ph.D. VP of Investor Relations & Communications NA
Ms. Robin E. Abrams J.D. Chief Legal Officer 1964
Ms. Tracy Mazza Clemente Chief People Officer NA
John Castle Head of Translational Medicine & Bioinformatics NA
Ms. Julie DeSander Chief Bus. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.